Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Completed · Phase 1

Conditions studied: Healthy

In brief

Primary Objective: Determine blood concentrations of two formulations of REGN1033. Secondary Objective: Assess safety and tolerability of REGN1033.

Key facts

Study ID

NCT02741739

Run by

Regeneron Pharmaceuticals

People needed

28

Starts

2016-03-01

Expected to finish

2016-05-01

Last updated by the study team

2016-10-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.